Levosimendans Pharmacokinetics in Intensive Care Patients. An Observational Study. (LEFKIP)
Levosimendans Pharmacokinetics in Intensive Care Patients
調査の概要
詳細な説明
Aims: To gain a better understanding of the pharmacokinetics of Levosimendan in critically ill patients and in particular in those patients with and without renal failure and in those receiving CRRT. This project may give a better basis to determine whether dose monitoring and adjustment of Levosimendan is necessary to avoid toxicity or under treatment. In order to study Levosimendan pharmacokinetics, the Karolinska laboratory has in parallel developed a method for analysis of the substance and its metabolites.
Research questions:
- To what extent are Levosimendan and its active metabolites dialysable in patients receiving continuous renal replacement therapy.
- How do the concentrations of Levosimendan and its active metabolites differ in critically ill patients with and without acute renal failure?
Method:
The is a prospective observational study conducted on adult intensive care units at Karolinska University Hospital.
Study Population: Critical care patients who due to clinical need are prescribed Levosimendan by treating physician will be included into one of three groups based on degree of AKI (KDIGO classification) and need for CRRT. This is a non-interventional study.
Number of patients to be included: we intend to include 4-12 patients per group.
Procedure: The decision to prescribe Levosimendan will be made by treating physicians as will decisions regarding dose, dose adjustment and length of treatment.
Screening for inclusion will occur when a decision to prescribe Levosimendan has been made.
Samples of blood, urine and ultrafiltration fluid from the CRRT circuit are to be analysed to determine concentration of Levosimendan and its metabolites. Plasma concentrations will be obtained, before and after the dialysis filter.
Concentration monitoring will occur over a period of up to 6 days, with test taken at 0, 6 and 20 hours after infusion start and after cessation of Levosimendan every two hours for the first 10 hours and there after twice a day for the next 5 days. A maximum of 30 samples (15 in non CRRT patients) of 1-3ml are taken.
Patient groups:
Group 1: Levosimendan + no AKI or KDIGO AKI stage 1. Group 2: Levosimendan + KDIGO AKI stage 2-3, not CRRT Group 3: Levosimendan + KDIGO AKI stage 1-3 with CRRT.
Analysis:
Analysis of the plasma concentration of Levosimendan and its metabolites (OR-1896, OR-1855) is performed at the clinical pharmacology department, Karolinska University Hospital. Reference substances have been provided by Orion Pharma.
Definitions:
Acute Kidney Failure (AKI) is defined according to the KDIGO definition: Creatinine entry from the baseline (percentage increase) and volume of urine production or CRRT treatment.
研究の種類
入学 (予想される)
連絡先と場所
研究連絡先
- 名前:Claire Rimes-Stigare, MD, PhD
- 電話番号:004651770000
- メール:claire.rimes-stigare@regionstockholm.se
研究連絡先のバックアップ
- 名前:Susanne Rysz, MD, PhD
- 電話番号:004651770000
- メール:susanne.rysz@regionstockholm.se
研究場所
-
-
-
Stockholm、スウェーデン
- 募集
- Karolinska University Hospital
-
コンタクト:
- Claire Rimes-Stigare, MD, PhD
- 電話番号:004651770000
- メール:claire.rimes-stigare@regionstockholm.se
-
コンタクト:
- Susanne, MD
- 電話番号:004651770000
- メール:sussanne.rysz@regionstockholm.se
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Intensive Care Unit patients in whom the treating physician has decided due to clinical indication to administer levosimendan. Dose and length of treatment decided by treating physician.
With Group 1: No renal failure or Acute Kidney Injury(AKI)* stage 1. Group 2: AKI stage 2-3, not receiving renal replacement therapy. Group 3: Receiving continuous renal replacement therapy (CRRT)
*AKI classification system Kidney Disease Improving Global outcomes (KDIGO)
説明
Inclusion Criteria:
° Adult Intensive care patients in whom treating physicians have judged to be in need of Levosimendan treatment.
Exclusion Criteria:
- Patient <18 years of age
- Pregnancy
- Patients receiving Intermittent hemodialysis
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Concentration of levosimendan and OR 1896 1855 in plasma
時間枠:1-5 days
|
Plasma concentrations of levosimendan and its active metabolites afte Levosimendan infusion.
|
1-5 days
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。